# Lymphoma & Leukemia Research Program (Project-007)

> **NIH NIH P30** · STANFORD UNIVERSITY · 2020 · $43,892

## Abstract

PROJECT SUMMARY – LYMPHOMA & LEUKEMIA PROGRAM 
The goal of the Lymphoma and Leukemia (LL) Program is to gain a better understanding of the biology 
underlying lymphoid and myeloid neoplasms and to apply this knowledge to improve the diagnosis and 
treatment of these disorders. In working toward this goal, this broad research program encompasses major 
aims of disease pathogenesis, clinical pathological relationships, the use of biomarkers in patient 
stratification, novel therapeutics, and clinical trials. Program members have emphasized translational 
research to the clinic in diagnostics and novel therapeutics, and from the clinic to the laboratory in 
correlative studies on tissues matched with clinical events. The laboratory-based projects are focused on 
the characterization of leukemia stem cells; elucidation of signaling pathways in individual tumor cells; 
determination of mechanisms of lymphomagenesis with specific attention to the MYC oncogene, and 
analysis of the role of the immune system in specific relation to lymphomas and leukemias. Novel 
diagnostics have been developed, including the discovery of founder genetic mutations and novel tests for 
monitoring tumor responses using cell-free DNA. The LL Program has developed new ways of enhancing 
the therapeutic activity of monoclonal antibodies by stimulating NK killer cells (anti-CD137), novel drug- 
antibody conjugates (Brentuximab Vedotin), and a new method of therapeutic vaccination (in situ 
vaccination with TLR9 ligands and immune checkpoint antibodies). Program members have also played 
major roles in the development of novel targeted therapies (BTK inhibitor, Ibrutinib, and the PI3 kinase delta 
inhibitor, Idealisib). Studies from the program have been influential in changing medical practice worldwide. 
Future plans include combining targeted small molecules with immunotherapies in the hope of replacing 
current cytotoxic chemotherapy regimens with safer, more effective therapies. 
Co-led by Ronald Levy, MD and Ravindra Majeti, MD, PhD the 24 LL Program members represent 11 
departments within the School of Medicine and the School of Engineering. Peer-reviewed funding is 
represented by a total of $6.7M in total annual costs of which $4.2M is from the NCI, $0.9M from other NIH 
sources, and $1.7M from other peer-reviewed support mechanisms. Since 2009, program investigators 
have published over 375 manuscripts, of which 28% are intra-programmatic, 32% inter-programmatic, and 
numerous manuscripts with external collaborators. The SCI will continue to be invaluable in the seeding of 
innovative projects and assisting with the translation of basic science findings of this program into new 
clinical approaches for the diagnosis and treatment of patients with Lymphoma and Leukemia.

## Key facts

- **NIH application ID:** 9936166
- **Project number:** 5P30CA124435-13
- **Recipient organization:** STANFORD UNIVERSITY
- **Principal Investigator:** RONALD LEVY
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $43,892
- **Award type:** 5
- **Project period:** — → 2022-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9936166

## Citation

> US National Institutes of Health, RePORTER application 9936166, Lymphoma & Leukemia Research Program (Project-007) (5P30CA124435-13). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9936166. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*